September 26, 2016
View Full Paper2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Key Result
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are key pharmacological therapies updated in the 2016 ACC/AHA/HFSA guidelines for the management of heart failure.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
◼ angioedema ◼ angiotensin-converting enzyme inhibitors ◼ angiotensin receptor blockers ◼ angiotensin receptor
Cite This Study
Yancy et al. (Mon,) reported a other. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are key pharmacological therapies updated in the 2016 ACC/AHA/HFSA guidelines for the management of heart failure.